Interest in psilocybin therapy has grown rapidly in California and across the United States, but one question continues to come up: When will psilocybin therapy actually receive FDA approval?
For the first time, there may be a reasonably clear answer. A psilocybin-based treatment has completed two successful Phase 3 clinical trials, an FDA review process is already underway, and the company developing the treatment is preparing for a potential commercial launch during the first half of 2027.
That does not mean psilocybin therapy is currently FDA approved. It isn’t. But the regulatory process has advanced substantially, and 2027 is emerging as a potentially important year for psychedelic-assisted treatment in the United States.
Is Psilocybin Therapy FDA Approved?
No. As of August 2026, the FDA has not approved psilocybin therapy for depression, anxiety, PTSD, or another psychiatric condition.
Psilocybin remains an investigational treatment at the federal level. The treatment currently closest to possible approval is COMP360, a proprietary synthetic psilocybin formulation developed by Compass Pathways for treatment-resistant depression (TRD).
This distinction is important. An FDA approval of COMP360 would not mean that psilocybin mushrooms generally become an approved medical treatment. It would mean that a specific pharmaceutical psilocybin product could be prescribed and administered according to the conditions established through the FDA approval process.
Why 2027 Could Be the Year Psilocybin Therapy Is Approved
The timeline has accelerated considerably during 2026.
Compass Pathways has now reported positive results from two Phase 3 clinical trials evaluating COMP360 in people with treatment-resistant depression. In its second Phase 3 trial, the company reported a statistically significant reduction in depression severity, with benefits among responding patients extending through six months.
Phase 3 trials are generally the final major stage of clinical testing before a company seeks FDA approval of a new medication.
Compass has gone a step further. The FDA granted the company permission to make a rolling New Drug Application (NDA) submission, allowing portions of the application to be submitted and reviewed before the entire application is complete. Compass reported in August that the rolling submission and initial FDA review were already underway and that it expects to complete its final NDA submission during the fourth quarter of 2026.
That puts a potential FDA decision within sight.
Could Psilocybin Be Approved as Early as Early 2027?
Possibly, although there is no guaranteed FDA approval date.
Compass has received a Commissioner’s National Priority Voucher for COMP360. According to the company, the voucher has the potential to shorten the FDA review following completion of the application to approximately one to two months. The company currently says it expects a commercial launch in the first half of 2027, assuming the treatment receives regulatory approval.
That has fueled speculation that an FDA decision could potentially arrive very early in 2027.
However, patients should be cautious about interpreting any specific month as an established approval date. The FDA has not announced that COMP360 will be approved in January or on any other specific date. The agency still has to evaluate the completed application, and approval is never guaranteed simply because a treatment successfully completes Phase 3 trials.
What has changed is that a potential 2027 approval is no longer a distant theoretical possibility. There is now an active regulatory pathway that could lead there.
What Is Treatment-Resistant Depression?
The initial COMP360 application is focused on treatment-resistant depression, rather than depression generally.
Treatment-resistant depression typically refers to depression that has not adequately improved after multiple conventional treatments. Participants in Compass’s Phase 3 program represented a particularly difficult-to-treat population. Across the company’s trials, participants had experienced their current depressive episodes for an average of more than three years and had experienced more than six depressive episodes during their lifetimes.
This matters because an initial FDA approval would likely be relatively narrow. Psilocybin would not suddenly become an approved treatment for every mental health condition for which it is currently being studied.
Other potential indications would require their own supporting research and regulatory approvals.
What Would FDA-Approved Psilocybin Treatment Look Like?
FDA-approved psilocybin treatment is unlikely to resemble simply receiving a prescription and taking medication at home.
The clinical model being developed around COMP360 involves administration in a controlled healthcare setting with psychological support and an extended period of monitoring. Compass has been preparing healthcare providers and treatment facilities for this type of delivery model and says existing facilities offering multi-hour psychiatric treatments could potentially provide much of the infrastructure needed.
Exactly what requirements will accompany an FDA approval remains to be determined. Federal scheduling, state regulations, provider qualifications, insurance coverage and treatment protocols could all affect how quickly patients actually gain access.
So there could be an important difference between FDA approval and widespread availability.
What Would FDA Approval Mean for California?
California has one of the country’s largest populations of patients interested in psychedelic-assisted treatment, but FDA approval would not automatically create unrestricted access to psilocybin throughout the state.
Federal drug scheduling would still have to be addressed, and California could have additional regulatory requirements governing where treatment can occur and who can provide it.
The federal government is already preparing for some of these issues. In April 2026, the FDA announced new actions intended to accelerate the development of treatments for serious mental illness, specifically including psychedelic medications.
For Californians interested in treatment, the most realistic expectation is therefore a gradual transition from clinical research into a highly regulated medical treatment model rather than immediate broad availability.
Can You Receive Psilocybin Therapy in California Right Now?
There is currently no FDA-approved psilocybin therapy available through ordinary medical practice in California.
Compass also states that it is not currently providing expanded access to COMP360 outside its clinical research programs while the treatment moves through the NDA process.
Patients should be especially careful with businesses or individuals claiming to offer “FDA-approved psilocybin therapy” today. That approval does not yet exist.
There are, however, currently available treatments that use some elements of the broader psychedelic-assisted treatment model. Ketamine, for example, is legally available through appropriately licensed medical providers and is sometimes combined with psychotherapy or integration-oriented support.
What Happens Next?
The next major milestone is completion of the COMP360 New Drug Application, which Compass expects during the fourth quarter of 2026. The FDA will then determine whether the evidence supports approval for treatment-resistant depression.
If the accelerated regulatory timeline works as anticipated, a decision could potentially follow relatively quickly. Compass is already preparing for a commercial launch during the first half of 2027.
For people following psychedelic medicine for years, this represents a significant change. The conversation is increasingly moving away from whether a psychedelic treatment might someday reach the FDA and toward when the first FDA-approved psilocybin treatment could actually become available.
For now, the most accurate answer is that psilocybin therapy is not yet FDA approved, but COMP360 could potentially receive approval in 2027 if its application is successfully completed and accepted by the FDA.
Learn More About Psychedelic Therapy in California
Whether you’re exploring treatment options or looking for information specific to your region, continue your research with these guides.
Treatment Guides
- MDMA Therapy in California
- Psilocybin Therapy in California
- Ketamine Therapy
- Psychedelic Integration Therapy
- Psychedelic Clinical Trials California
Regional Guides
- Bay Area Psychedelic Therapy Guide
- Los Angeles Psychedelic Therapy Guide
- Orange County Psychedelic Therapy Guide
- San Diego Psychedelic Therapy Guide
- Sacramento Psychedelic Therapy Guide
- San Jose Psychedelic Therapy Guide
- Silicon Valley Psychedelic Therapy Guide
- Inland Empire Psychedelic Therapy Guide
- Central Coast Psychedelic Therapy Guide